Iovance Biotherapeutics Eyes Global Expansion Amid High-Risk Growth Profile

Iovance Biotherapeutics (NASDAQ: IOVA) is attempting to pivot from a long-term decline toward sustainable growth, driven by the commercial rollout of its melanoma therapy, Amtagvi. While the stock has risen 34% year-to-date in 2026, it remains significantly below its historical peaks, having lost approximately 90% of its value over the past five years. The company reported 2025 total revenue of $263.5 million, representing a nearly 61% increase over the previous year. This top-line growth is primarily attributed to the U.S. performance of Amtagvi. Management is now focusing on expanding the drug's reach, with recent approval in Canada and planned launches in Europe and Australia. Beyond melanoma, Iovance is targeting the lung cancer market, which represents a larger addressable opportunity. Provided clinical trials for the active ingredient lifileucel proceed as planned and secure regulatory approval, the company aims to launch the treatment for lung cancer in 2027. However, the path to profitability is complicated by the nature of tumor-infiltrating lymphocyte (TIL) therapies. Because these treatments are manufactured from a patient's own cells, they cannot be produced at scale and are complex to administer. This creates friction with third-party payers and requires expensive infrastructure for commercialization. While some Wall Street analysts maintain an average price target of $9—suggesting a potential upside of 165%—the company's success depends on near-perfect execution of its clinical and regional expansion strategies. Failure to meet upcoming milestones could lead to significant share price volatility.